Please login to the form below

Not currently logged in
Email:
Password:

erlotinib

This page shows the latest erlotinib news and features for those working in and with pharma, biotech and healthcare.

Tagrisso tops rival drugs on survival in first-line lung cancer

Tagrisso tops rival drugs on survival in first-line lung cancer

The improvement in OS came over other drugs in the EGFR inhibitor class, namely AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib), and according to AZ’s head of

Latest news

More from news
Approximately 4 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Market access opportunities in China Market access opportunities in China

    For example, although Roche's Tarceva (erlotinib hydrochloride) has not been included in any reimbursement lists in China, it has paved the way by collaborating with the China Charity Federation to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Novocure’s chief commercial officer to step down Novocure’s chief commercial officer to step down

    Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

  • Astellas poaches new oncology head from Takeda Astellas poaches new oncology head from Takeda

    She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

  • Cipla appoints Novartis’ Subhanu Saxena as CEO Cipla appoints Novartis’ Subhanu Saxena as CEO

    Cipla has also been busy challenging big pharma patents, and in September won a four-year battle to market its own version of Roche's cancer drug  Tarceva  (erlotinib).

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics